Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer

E Agostinetto, A Losurdo, G Nader-Marta… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Triple negative breast cancer (TNBC) is an area of high unmet medical need in
terms of new effective treatment strategies. Although breast cancer is traditionally …

[HTML][HTML] Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation

V Wischnewski, RR Maas, PG Aruffo, K Soukup… - Nature Cancer, 2023 - nature.com
The immune-specialized environment of the healthy brain is tightly regulated to prevent
excessive neuroinflammation. However, after cancer development, a tissue-specific conflict …

Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature

A Losurdo, S Rota, G Gullo, G Masci, R Torrisi… - Critical reviews in …, 2017 - Elsevier
Male breast cancer (MaBC) is a rare disease, accounting for less than 1% of malignancies in
men. For this reason, literature data on its clinicopathological characteristics are very …

Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what?

R Torrisi, E Marrazzo, E Agostinetto… - Critical Reviews in …, 2021 - Elsevier
Indication for neoadjuvant chemotherapy (NACT) in HR+/HER2-negative tumors is
controversial. Pathological complete response (pCR) rates range from 0 to 18% while breast …

[HTML][HTML] MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in …

L De Mattos-Arruda, G Bottai, PG Nuciforo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Patients with primary HER2-positive breast cancer benefit from HER2-targeted therapies.
Nevertheless, a significant proportion of these patients die of disease progression due to …

[HTML][HTML] IRF4 instructs effector Treg differentiation and immune suppression in human cancer

G Alvisi, J Brummelman, S Puccio… - The Journal of …, 2020 - Am Soc Clin Investig
The molecular mechanisms responsible for the high immunosuppressive capacity of CD4+
Tregs in tumors are not well known. High-dimensional single-cell profiling of T cells from …

[HTML][HTML] An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers

G Bottai, C Raschioni, A Losurdo, L Di Tommaso… - Breast Cancer …, 2016 - Springer
Background Stromal tumor-infiltrating lymphocytes (TILs) are a robust prognostic factor in
triple-negative breast cancer (TNBC). However, the clinical significance of TILs may be …

Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series

G Masci, M Caruso, F Caruso, P Salvini… - The …, 2015 - academic.oup.com
Background. Due to its rarity, male breast cancer (mBC) remains an inadequately
characterized disease, and current evidence for treatment derives from female breast cancer …

[HTML][HTML] Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

E Zattarin, D Presti, L Mariani, C Sposetti… - NPJ Breast …, 2023 - nature.com
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has
prognostic significance in HR+/HER2-advanced Breast Cancer (aBC) patients treated with …

[HTML][HTML] AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

G Bottai, C Raschioni, B Székely, L Di Tommaso… - NPJ breast …, 2016 - nature.com
A subgroup of triple-negative breast cancer (TNBC) shows epithelial-to-mesenchymal
transition (EMT) features, which are sustained by the interaction between cancer cells and …